Albireo Pharma is a biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company's primary product candidate, A4250, is used for the treatment of progressive familial intrahepatic cholestasis (PFIC), pruritus associated with PFIC, Alagille syndrome and biliary atresia. The company's product candidates in addition to A4250 include elobixibat, which is approved in Japan for the treatment of chronic constipation, and A3384, which is a product candidate to treat bile acid malabsorption.

Avenue Therapeutics is a pharmaceutical company that acquires, licenses, develops and commercializes products principally for use in the acute/intensive care hospital setting. The company's product candidate is intravenous Tramadol, for the treatment of moderate to moderately severe post-operative pain. The company's product candidate, Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level.

CalAmp is a telematics solutions provider. The company's software applications, cloud services, and intelligent devices collect and assess data including industrial machines, commercial and passenger vehicles, their drivers and contents. The company operates under two reportable segments: Telematics Systems, which provide a series of telematics and stolen vehicle recovery products for the connected vehicle and emerging Internet of Machines marketplace; and Software and Subscription Services, which provide cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open Application Programming Interfaces.

Dave & Buster's Entertainment is an owner and operator of entertainment and dining venues (stores) that operate under the name Dave & Buster's. The company's concept is to provide its customers the opportunity to Eat Drink Play and Watch all in one location for adults and families, while serving food and beverages. The company's Eat and Drink is provided through a menu of entrees and appetizers and a selection of non-alcoholic and alcoholic beverages. The company's Play and Watch offerings provide an assortment of entertainment attractions centered around playing games and watching live sports and other televised events.

Exact Sciences is a molecular diagnostics company, focused on the early detection and prevention of cancer. The company has developed a non-invasive screening test called Cologuard? for the early detection of colorectal cancer and pre-cancer. The company's Cologuard test is a non-invasive stool-based DNAscreening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company is also working on the development of additional tests for other types of cancer. The company is also focusing its research and development efforts on building a pipeline of potential future products and services with a focus on blood-based tests.

Inspirit Energy Holding is engaged in the development and commercializing of micro Combined Heat and Power (mCHP) boiler for use in commercial and residential markets. The mCHP boiler is powered by natural gas and designed to produce hot water (for domestic hot water or central heating) and a simultaneous electrical output that can be used locally or fed back into the National Grid.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.